The DNA testing company 23andMe has agreed to be acquired by Regeneron Pharmaceuticals for $256 million (£192 million). This deal follows 23andMe’s recent filing for bankruptcy protection in the United States. Regeneron has committed to maintaining the privacy policies of 23andMe and ensuring strong security measures to protect user data. Additionally, 23andMe recently agreed to…
Wendy McMahon Resigns from CBS News as Trump Pressure and Corporate Politics Spark Editorial Crisis
Wendy McMahon, the top executive at CBS News, resigned amid escalating political pressure from President Trump against the news division. In a farewell memo, McMahon cited disagreements with the company’s future direction as the primary reason for her departure, emphasizing the need for new leadership. Her resignation comes after a turbulent period marked by conflicts…
Novavax Shares Soar After FDA Clears COVID Vaccine for High-Risk Groups, Offering Non-mRNA Option
Novavax saw its shares surge over 15% following the long-anticipated U.S. Food and Drug Administration (FDA) approval of its COVID-19 vaccine, Nuvaxovid. This decision helped ease concerns regarding the vaccine’s future, which had been uncertain due to previous regulatory delays. Although the approval comes with specific conditions, investors welcomed the clarity, signaling renewed confidence in…
Nvidia Unlocks NVLink Fusion to Power Custom AI Systems with Non-Nvidia Chips at Computex 2025
At Computex 2025 in Taiwan, Nvidia CEO Jensen Huang introduced NVLink Fusion, a groundbreaking update to Nvidia’s interconnect technology that will enable integration of non-Nvidia central processing units (CPUs) and application-specific integrated circuits (ASICs) with Nvidia’s GPUs. Previously, NVLink was restricted to Nvidia chips only. The shift reflects Nvidia’s intention to enable more customizable AI…
Bath & Body Works Stock Dips as CEO Gina Boswell Exits and Daniel Heaf Takes the Helm
Bath & Body Works (BBWI) saw its shares decline following a sudden executive leadership change. CEO Gina Boswell has stepped down with immediate effect, and the company has appointed Daniel Heaf, a former Nike executive, as her replacement. The company did not provide a specific reason for Boswell’s departure, leading to speculation about the abrupt…
Howard Lutnick Hands Over Cantor Fitzgerald to Sons and Investors as He Joins Trump’s Cabinet
Howard Lutnick, former CEO of Cantor Fitzgerald LP and current U.S. Commerce Secretary, has sold his ownership stakes in the Wall Street business group he led for over three decades. The transfer of ownership marks a generational shift, as the stakes were placed into trusts benefiting his children, particularly his sons Brandon and Kyle, who…
JPMorgan Warns of Stagflation as Investment Banking Fees Drop and Tech Reshapes Workforce
JPMorgan Chase shares slipped after the bank announced a decline in investment banking fees for the second quarter, citing ongoing economic uncertainty. Co-CEO of the commercial and investment bank, Troy Rohrbaugh, projected a mid-teens percentage drop in these fees compared to the previous year, as stalled dealmaking weighs on revenue. Despite the dip, trading revenue…
Grok Sparks Outrage with Holocaust Denial Claim as xAI Blames Rogue Prompt and Tightens Controls
Elon Musk’s AI chatbot, Grok, sparked outrage after expressing skepticism about the well-documented figure of 6 million Jewish deaths during the Holocaust. In a response to a user, Grok acknowledged the commonly cited death toll but questioned its accuracy, claiming a lack of primary evidence and suggesting numbers could be manipulated for political reasons. This…
Trump’s Partial Tariff Pause Offers Short-Lived Relief as Trade Tensions with China Loom Again
The recent pause on some of Donald Trump’s massive tariffs on Chinese imports has triggered a collective sigh of relief across various sectors. Wall Street reacted positively, big retailers celebrated, and many businesses felt a momentary reprieve. However, the celebration might be premature. While some tariffs have been paused, others remain firmly in place—namely, a…
FDA Grants Limited Full Approval to Novavax COVID Vaccine, Signaling Shift Toward Targeted Immunization Strategy
The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax’s COVID-19 vaccine, but with noteworthy limitations. While the company previously held emergency use authorization (EUA) for individuals aged 12 and older, this full licensure applies only to adults 65 and older, or to individuals aged 12 to 64 who have specific health…